

# Comparing cotrimoxazole to standard care for the treatment of severe coronavirus (COVID-19) infection in hospitalised patients

<b>Submission date</b> 05/02/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 09/02/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 15/11/2022	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe. At least 15-20% of those who are infected progress to severe COVID-19 disease.

In a small number of patients, there may be a misdirected immune response to the infection, causing inflammation of the lungs and respiratory failure. This response may also cause increased clotting of the blood. Currently, there is no evidence-based, specific anti-viral treatment available for COVID-19, and recommended treatment is supportive with steroids and low molecular weight heparin.

Co-trimoxazole (combination of trimethoprim and sulphamethoxazole) is an antibiotic that kills bacteria. Co-trimoxazole is effective against a wide range of bacterial infections including respiratory tract infections. It has been used for over 80 years and is well-tolerated, inexpensive, and readily available. In addition to having fighting bacterial infections, co-trimoxazole has an effect on the immune system and anti-inflammatory properties. Therefore, co-trimoxazole may be a potential treatment option severe COVID-19.

This study will investigate if starting cotrimoxazole treatment early in hospitalised COVID-19 patients could prevent the development of the disease to a critical stage.

### Who can participate?

All adult patients admitted to Medical College Hospital, Kolkata with severe COVID-19 infection

### What does the study involve?

Participants will be allocated to one of two groups, with an equal chance of being in either group

(like tossing a coin). Participants and researchers will not have a choice in the treatment given. The first group of participants will receive the study drug, cotrimoxazole, plus standard care. They will be asked to take cotrimoxazole by mouth, three times daily, for 7 days. Treatment with drugs or procedures that the clinician responsible for the participant feels is necessary and would be part of routine clinical practice will be allowed. The other group will receive only the necessary drugs or procedures in routine clinical practice according to the best standard of care and local guidance.

What are the possible benefits and risks of participating?

All participants in this study shall have the privilege of additional (beyond routine care) closer and more intense medical attention. Co-trimoxazole is a time-tested, relatively well-tolerated drug that has been in clinical use for around five decades. Appropriate cautions shall be exercised by the investigators to guard against the known side effects of the drug. In case of any rare serious complication, urgent treatment shall be provided free of cost.

Where is the study run from?

School of Tropical Medicine, Kolkata (India)

When is the study starting and how long is it expected to run for?

October 2020 to March 2023

Who is funding the study?

Department of Health and Family Welfare, Govt of West Bengal (India)

Who is the main contact?

Prof (Dr) Bibhuti Saha

bibhuti.saha@gmail.com

## Contact information

### Type(s)

Scientific

### Contact name

Prof Bibhuti Saha

### Contact details

Department of Tropical Medicine

School of Tropical Medicine

108 Chitta Ranjan Avenue

Kolkata

India

700073

+919831296071

bibhuti.saha@gmail.com

### Type(s)

Public

### Contact name

Dr Syed Rehan Quadery

**ORCID ID**

<http://orcid.org/0000-0002-9261-010X>

**Contact details**

St. Helier Hospital  
Wrythe Lane  
Sutton  
Sutton  
United Kingdom  
SM5 1AA  
+44 9800649068  
rehan.quadery@nhs.net

**Type(s)**

Scientific

**Contact name**

Prof Udas Chandra Ghosh

**Contact details**

Department of Medicine  
Medical College and Hospital  
88 College Street  
Kolkata  
India  
700073  
+91 9433044237  
udasghosh23@gmail.com

**Additional identifiers****EudraCT/CTIS number**

Nil known

**IRAS number****ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

CTRI/2021/02/031012

**Study information****Scientific Title**

Cotrimoxazole in hospitalised patients with severe COVID-19 infection compared to the standard of care – an investigator-initiated, randomised controlled trial

**Acronym**

## **Study objectives**

Use of oral cotrimoxazole in patients with severe COVID-19 can prevent 'higher' oxygenation requirements through non-invasive and invasive mechanical ventilation, decrease in-hospital stays, and decrease death rate

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

1. Approved 09/01/2021, Institutional Ethics Committee, Medical College Kolkata (88, College St, Calcutta Medical College, College Square, Kolkata, West Bengal 700073; +919433084372; no email address available), ref: MC/KOL/IEC/NON-SPON/863/01/2021
2. Approved 14/01/2021, Clinical Research Ethics Committee (Calcutta School of Tropical Medicine, 108 Chitta Ranjan Avenue, Kolkata 700073; +919433349332; smnaser2012@gmail.com), ref: CREC-STM/2020-AS-18

## **Study design**

Single-centre randomized controlled trial

## **Primary study design**

Interventional

## **Secondary study design**

Randomised controlled trial

## **Study setting(s)**

Hospital

## **Study type(s)**

Prevention

## **Participant information sheet**

See additional file ISRCTN85874083\_PIS\_v1.0\_09Feb2021 (added 01/03/2021)

## **Health condition(s) or problem(s) studied**

Hospitalized patients with severe COVID-19 (SARS-CoV-2 infection)

## **Interventions**

Current intervention as of 14/11/2022:

Randomisation to treatment arms cotrimoxazole plus standard of care or standard of care only in a 1:1 ratio will be performed using an internet-based randomisation tool.

The intervention group, cotrimoxazole plus standard of care, will receive oral cotrimoxazole 960 mg three times daily for 7 days. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed.

The control group will receive drugs or procedures in routine clinical practice according to the best standard of care as per local protocol.

---

Previous intervention:

Randomisation to treatment arms cotrimoxazole plus standard of care or standard of care only in a 2:1 ratio will be performed using an internet-based randomisation tool.

The intervention group, cotrimoxazole plus standard of care, will receive oral cotrimoxazole 960 mg three times daily for 7 days. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed.

The control group will receive drugs or procedures in routine clinical practice according to the best standard of care as per local protocol.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

cotrimoxazole

### **Primary outcome measure**

Current primary outcome measure as of 15/11/2022:

Number of in-patient deaths measured from patient records between baseline and hospital discharge or death

---

Previous primary outcome measure:

1. Clinical status, the number of patients requiring escalation of care to non-invasive ventilation (CPAP and HFNC) and invasive ventilation measured using the 7-point ordinal scale (scored from 1 to 7 as follows: 1= death; 2= hospitalised, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalised, requiring non-invasive ventilation or high flow oxygen devices; 4= hospitalised, requiring supplemental oxygen; 5= hospitalised, not requiring supplemental oxygen, but in need of ongoing medical care (COVID-19 related or otherwise), 6= hospitalised, not requiring supplemental oxygen and no longer requires ongoing medical care (independent); or 7= not hospitalised) between baseline and hospital discharge or death
2. Duration of hospitalisation measured from patient records between baseline and hospital discharge or death
3. Number of in-patient deaths measured from patient records between baseline and hospital discharge or death

### **Secondary outcome measures**

Current secondary outcome measures as of 15/11/2022:

1. Clinical status, the number of patients requiring escalation of care to non-invasive ventilation (CPAP and HFNC) and invasive ventilation measured using the 7-point ordinal scale (scored from 1 to 7 as follows: 1= death; 2= hospitalised, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalised, requiring non-invasive ventilation or high flow oxygen devices; 4= hospitalised, requiring supplemental oxygen; 5= hospitalised, not requiring supplemental oxygen, but in need of ongoing medical care (COVID-19 related or otherwise), 6= hospitalised, not requiring supplemental oxygen and no longer requires ongoing medical care (independent); or 7= not hospitalised) between baseline and hospital discharge or death
  2. Time to recovery measured from patient records between baseline and hospital discharge or death
  1. Changes in COVID-19 severity measured using the following at baseline, 3, and 7 days:
    - 1.1. Body temperature measured using a thermometer
    - 1.2. Respiratory rate measured using manual method
    - 1.3. Serum levels of C-reactive protein (CRP) measured from blood samples
    - 1.4. Oxygen saturation measured using a pulse oximeter
  2. Incidence of serious and non-serious adverse events measured from patient records between baseline and hospital discharge or death
- 

Previous secondary outcome measures:

1. Changes in COVID-19 severity measured using the following at baseline, 3, and 7 days:
  - 1.1. Body temperature measured using a thermometer
  - 1.2. Respiratory rate measured using manual method
  - 1.3. Serum levels of C-reactive protein (CRP) measured from blood samples
  - 1.4. Oxygen saturation measured using a pulse oximeter
2. Incidence of serious and non-serious adverse events measured from patient records between baseline and hospital discharge or death

### **Overall study start date**

01/10/2020

### **Completion date**

01/03/2023

## **Eligibility**

### **Key inclusion criteria**

Current inclusion criteria as of 14/11/2022:

1. Adult male or female individuals, age  $\geq 18$  years and  $\leq 70$  years
  2. Patients giving written informed consent to participate in the study (i.e. GCS 15/15: conscious, alert, and oriented)
  3. COVID-19 documented by a positive RT-PCR test/Rapid Antigen Test
  4. Hospitalised patients with severe COVID-19, requiring supplemental oxygen through a non-re-Breath mask between 10-15 l/min maintaining saturations between 92-96% for up to 30 h and between 94-98% for the first 6 h
  5. Clinical/radiological evidence of interstitial pneumonia requiring admission (optional)
-

Previous inclusion criteria as of 13/05/2021:

1. Adult male or female individuals, age  $\geq 18$  years and  $\leq 65$  years
2. Patients giving written informed consent to participate in the study (i.e. GCS 15/15: conscious, alert, and oriented)
3. COVID-19 documented by a positive RT-PCR test/Rapid Antigen Test
4. Hospitalised patients with severe COVID-19, requiring supplemental oxygen through a non-re-Breath mask between 10-15 l/min maintaining saturations between 92-96% for up to 30 h and between 94-98% for the first 6 h
5. Clinical/radiological evidence of interstitial pneumonia requiring admission (optional)

---

Previous inclusion criteria:

1. Aged between 18 and 65 years
2. COVID-19 infection documented by a positive RT-PCR test
3. Hospitalised with severe COVID-19 infection, characterized by fever (at the time of screening or when admitted) and requiring supplemental oxygen through non-rebreather mask between 10 and 15 l/min
4. Clinical/radiological evidence of interstitial pneumonia requiring admission (optional)
5. Informed written consent given

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Lower age limit**

18 Years

### **Sex**

Both

### **Target number of participants**

110

### **Key exclusion criteria**

Current exclusion criteria as of 13/05/2021:

1. Patients who require invasive or non-invasive (including CPAP and high flow nasal cannula). ventilation at the time of inclusion
2. AST/ALT values  $>5$  fold the upper normal limit
3. Impairment of renal function( creatinine clearance $<30$ ml/min/m<sup>2</sup>)
4. Absolute neutrophil count below 500 cells/mm<sup>3</sup>
5. Absolute platelet count below 50,000 cells/mm<sup>3</sup>
6. Documented sepsis or high clinical suspicion of superimposed severe bacterial or fungal infection
7. Concomitant acute medical emergencies, such as AMI, acute pericarditis, PE, stroke, acute Surgical and orthopaedic emergencies like acute abdomen and fractured neck of femur etc.

8. Comorbidities or concomitant medications likely to be incompatible for cotrimoxazole use
9. History of cotrimoxazole hypersensitivity
10. Patients participating in another clinical trial for SARS-CoV-2 infection

---

Previous exclusion criteria:

1. Require invasive or non-invasive (including CPAP and high flow nasal cannula) ventilation at the time of inclusion
2. Aspartate transaminase (AST)/alanine transaminase (ALT) ratio >5 times the ULN
3. Documented impairment of renal function
4. Absolute neutrophil count <500 cells/mm<sup>3</sup>
5. Absolute platelet count <50,000 cells/mm<sup>3</sup>
6. Documented sepsis or high suspicion of superimposed severe bacterial or fungal infection
7. Comorbidities or concomitant medications likely to be incompatible for cotrimoxazole use
8. Pregnancy or lactation
9. History of cotrimoxazole hypersensitivity
10. Participating in another clinical trial for SARS-CoV-2 infection

**Date of first enrolment**

15/02/2021

**Date of final enrolment**

01/09/2022

## **Locations**

**Countries of recruitment**

India

**Study participating centre**

**Medical College and Hospital, Kolkata**

88, College St

Calcutta Medical College

College Square

Kolkata

India

700073

**Study participating centre**

**School of Tropical Medicine, Kolkata**

School Of Tropical Medicine

108, Chitta Ranjan Avenue



Kolkata  
India  
700073

## Sponsor information

### Organisation

School of Tropical Medicine, Kolkata

### Sponsor details

108 Chitta Ranjan Avenue  
Kolkata  
India  
700073  
+919831234802  
directorstm18@gmail.com

### Sponsor type

Government

### Website

<http://www.stmkolkata.org/>

## Funder(s)

### Funder type

Government

### Funder Name

Department of Health and Family Welfare, Government of West Bengal

### Alternative Name(s)

### Funding Body Type

Government organisation

### Funding Body Subtype

Local government

### Location

India

# Results and Publications

## Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

## Intention to publish date

01/09/2023

## Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication

## IPD sharing plan summary

Other

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	version v1.0	09/02/2021	01/03/2021	No	Yes
<a href="#">Protocol file</a>	version v2.0	24/12/2020	01/03/2021	No	No